Impact of thalidomide therapy on liver and renal function
The serum biochemical findings concerning the hepatic and renal safety of thalidomide therapy revealed that the mean level of ALT reduced significantly (p ≤ 0.001) from 27.7 ± 20 IU/L at baseline to 22.8 ± 5.8 IU/L at 6th month of therapy, but no significant changes in the mean level of ALT were observed at 30th month of therapy when compared with baseline (Fig. Changes in ALT, bilirubin, creatinine and uric acid levels at different time intervals. Our data revealed no significant changes in the mean creatinine levels throughout the study duration (Fig. 